CARA

Cara Therapeutics, Inc. (CARA) | Rumor.io

Cara Therapeutics

CARA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CARA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 1

Cara Therapeutics Inc's stock price increased by 43.66% today.
The company focuses on developing new chemical entities to alleviate pain and pruritus.
The stock's notable movement may draw attention from those interested in market developments within the healthcare sector.

Generated by AI

Sentiment

Of the messages about CARA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.49% +2.75
Bearish	—	—	—	8.51% -2.75

Bullish· Dec 20

CARA has shown significant price movement, with a 71% increase this week, indicating strong buying power.
The asset's market capitalization of $22M is considered too low, suggesting potential for substantial growth, with some predicting a price of $2.
Breaking the $0.45 barrier could lead to a significant price increase, potentially reaching $0.7 by EOD, with some analysts expecting an easy move to $2 and potentially as high as $3.

Bearish· Dec 18

The company's drug failed a study and is being discontinued, leading to a significant price drop.
The company's cash reserves are significantly higher than its market capitalization, suggesting that it may be a waste of resources to continue operating.
The company's future prospects are bleak, with no near-term catalysts and a significant delay until the next approval, making it unlikely to recover in the near term.

Generated by AI

Topics

Of the messages about CARA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	70%
Controversies	—	—	—	0%
Earnings	—	—	—	30%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Earnings· May 4

Cara Therapeutics, Inc. ($CARA) reported a loss of $0.81 per share, missing estimates by $0.08.
The company beat revenue estimates by $0.80 million.
The stock's price movement is anticipated to be influenced by the upcoming earnings release, with some investors expecting a positive reaction to the company's pipeline of clinical studies.

Analysts· Jun 30

Analysts are overwhelmingly bullish on Cara Therapeutics, with 4/5 maintaining a buy rating and price targets ranging from $20 to $30.
Several firms have reiterated or upgraded their price targets for CARA, including H.C. Wainwright ($30), Piper Jaffray ($27), and Needham & Company ($undisclosed).
Downgrades are rare, with only Janney Montgomery Scott downgrading CARA to neutral, while Laidlaw and Stifel Nicolaus have cut their price targets to $30 and $20, respectively.

Announcements· Dec 31

Cara Therapeutics, Inc. announced a 1-for-12 reverse stock split.
No specific announcements were made by Cara Therapeutics, Inc. in the provided social media posts.
There is no market-relevant information provided in the social media posts about Cara Therapeutics, Inc.

Technical Analysis· Aug 25

$CARA has broken through VWAP and is currently trading at 13.81, with the potential to continue north.
$CARA is forming a double bottom pattern on the daily chart, which could lead to a reversal and a gap fill to $28 over the next 6 months.
$CARA is showing a cup and handle pattern on the 15-minute chart, indicating a potential buy signal between 14.20-14.35.

Generated by AI

Community

Of the messages about CARA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	10.42%
Newcomers	—	—	—	89.58%

Regulars· Dec 31

$CARA is mentioned alongside $OPTN and $EHVVF as stocks to buy for 2025, with $CARA being one of the five no-brainer artificial intelligence stocks.
$CARA is part of a list of stocks mentioned as having growth milestones and strategic visions outlined for 2025, alongside $GBUX and $EHVVF.
$CARA is included in a list of stocks mentioned as part of a broader announcement about making $EHVVF great again, alongside $OPTN.

Newcomers· Mar 7

The newcomer is focused on Cara Therapeutics' revenue, specifically the significant decrease in Q4 2022, which was $2.3M compared to $16.8M in Q2 2022.
The newcomer is concerned about the company's stock performance, with a significant loss of 0.56$ and a sharp decrease in sales from 3.26 million$ to an expected 16.25 million$.
The newcomer is reacting to the stock's sudden increase of 13.67% and the company's announcement of its fourth-quarter and full-year 2022 financial results, with Cara Therapeutics' stock price rising to $6.9.

Generated by AI

Also Discussed

Investors talking about CARA also mention

#	Name	Attention
1	ZYNE - Zynerba Pharmaceuticals, Inc.	——
2	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
3	22nd Century Group Inc.XXII	0%0
4	MACK - Merrimack Pharmaceuticals, Inc.	——
5	Corbus Pharmaceuticals Holdings, Inc.CRBP	0%0
6	iShares Biotechnology ETFIBB	0.01%0
7	PTC Therapeutics, Inc.PTCT	0%new
8	Exelixis Inc.EXEL	0%-0.03
9	The Scotts Miracle-Gro CompanySMG	0.01%new
10	Vericel CorporationVCEL	0%0